Navigation Links
Charting the Biosimilar and Biobetter Development Pipeline
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Charting the Biosimilar and Biobetter Development Pipeline

http://www.reportlinker.com/p0972502/Charting-the-Biosimilar-and-Biobetter-Development-Pipeline.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

 

 

 

Biosimilar development has failed to meet expectations in recent years, but that is set to change.

 

With a new U.S. biosimilars approval pathway imminent, and the expiration of many top-selling biologics on the horizon, existing biosimilar developers and newcomers are highly motivated to invest in the biosimilar field and are turning their attention to more complex biologics, such as monoclonal antibodies. Global sales of biologics are projected to reach $200bn in 2014 (from $138bn in 2010), making it a potentially lucrative market for biosimilar developers.

 

Originator, generics, and biosimilar companies alike need to be informed about the latest development trends and to know the likely patent expiration of marketed products and status of products in development. However, market intelligence has been widely dispersed, making it very difficult for companies to assess potential competition and areas of opportunity, until now.

 

FirstWord has gathered the very latest intelligence from BIOPHARMA, the Orange Book, literature, industry associations, company websites, and many other secondary sources to provide a single, authoritative guide to currently marketed and in-development biosimilar products.

 

 

 

Report Overview

In Charting the Biosimilar and Biobetter Development Pipeline , you'll find details of currently marketed biosimilar and biobetter drugs, and all biosimilar and biobetter drugs known to be in clinical development.

 

Through more than 60 intuitive tables and charts, you will receive unique insights into high-level trends and significant developments, and can easily drill down to details of a specific product or therapeutic area.

 

Need to know when Drug X will expire? Expiration dates for reference products draw on analysis of products, active agents, and manufacturing processes to go far beyond the Orange Book.

 

Need to know who is developing biobetters for interferons? Access a complete list with generic and candidate names, developers, reference products, and earliest possible EU/US launch dates.

 

The report's author has also included concise commentary throughout, providing valuable context and key insights.

 

For a complete guide to biosimilars at your fingertips, download Charting the Biosimilar and Biobetter Development Pipeline today.

 

 

 

Key Report Features

More than 60 exclusive tables and charts, offering a complete and illuminating view of the biosimilar pipeline

Up-to-the-minute details of ALL biosimilars/biobetters known to be in development in US and EU markets, with their development status and earliest potential launch dates

Information on international biogenerics that may seek approval as biosimilars/biobetters in US and EU markets

Comprehensive list of reference products, with key sales data and expected patent expiration dates

Detailed analysis of the biosimilar pipeline and market by reference products, therapeutic area, drug class, and compound class

Reports showing the most active companies, regions, and countries

Insights into areas of most intense competition and greatest potential opportunity

Concise commentary highlighting key findings, and providing valuable market intelligence

Definitions of key terms and concepts

 

 

 

Key Benefits

 

Understand the universe of biosimilar and biobetter development

Get the complete picture of all products in the biosimilar pipeline

Know the latest status on specific biosimilar andbiobetter products of interest to you

Read about the most significant developments in every therapeutic area

Discover the levels of potential biosimilar and biobetter competition by therapy area and drug class

Analyze the size of the threat to your company's biologic portfolio

Learn which companies are potential future competitors

 

 

Key Questions Answered

When is the earliest potential launch for "Biosimilar X"?

What biosimilars are being developed in each therapeutic area, drug class, and compound class?

Which reference products are most targeted by biosimilar and biobetter developers?

Is the reference product sales value the key factor shaping biosimilar development priorities?

Which therapy areas are going to experience the most and fewest biosimilar entries?

Which companies are most active in the biosimilar and biobetter arena?

Which biosimilar companies have been most successful in getting their products onto the market?

How many new biosimilars will be on the market by 2014?

 

Who Would Benefit From This Report?

Strategic executives at originator, generic, and biosimilar/biobetter development companies, especially in:

 

Sales and Marketing

Regulatory Affairs

IP and Patent Affairs

Market Research

Research & Development

Business Development

Medical Communications

 

 

 

Executive summary

Introduction

Definitions and methodology

> Scope and coverage

> Glossary

> Methodology

> Patents

> Indexing by indication

> Indexing by phase of development

> Nomenclature

Reference products

> Top20 Reference Products

Biosimilars in development

> Biosimilars by earliest potential launch date — US & EU

> Biosimilars by class and earliest potential launch date in the US (total number)

> Biosimilars by class and earliest potential launch date in the EU (total number)

> Biosimilar developers countries and regions

> Biosimilars in development by drug class

> Leading biosimilar companies - number of biosimilar products in portfolio

> Biosimilar development pipelines by compound class and therapy area

Biosimilar development pipelines by compound class

> Immunomodulators

> Interferons

> mAb Immunomodulators

> Cytotoxic mAbs

> Erythropoietin

> G-CSF

> Insulins

> Other Hormones (excluding insulins)

Biosimilar development pipelines by therapy area

> Endocrine and metabolic disorders

> Haematology

> Infectious and Parasitic Disease

> Musculoskeletal disorders

> Neurology

> Neuromuscular diseases

> Obstetrics/gynaecology

> Oncology

> Ophthalmology

Biobetters in development

> Biobetter developments by compound class and therapy area

> Biobetter development by therapy area and stage

> Biobetters by class and earliest potential launch in the US

> Biobetters by class and earliest potential launch in the EU

> Biobetter developers by compound class

Biobetter development pipeline by compound class

> Immunomodulators

> Interferons

> mAb Immunomodulators

> Cytotoxic mAbs

> Erythropoietins

> Others (Enzymes, Blood Clotting Factors)

> Other Hormones (excluding insulins)

Biobetter development pipeline by therapy area

> Autoimmune disease

> Autoinflammatory disease

> Cardiovascular diseases

> Dermatology

> Endocrine and metabolic disorder

> Haematology

> Infectious and parasitic disease

> Musculoskeletal disorders

> Neurology

> Obstetrics/gynaecology

> Oncology

> Respiratory disease

> Wound care

Product profiles

 

 

 

To order this report:

Biopharmaceutical Industry: Charting the Biosimilar and Biobetter Development Pipeline

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference
2. Artificial womb unlocks secrets of early embryo development
3. REST is crucial for the timing of brain development
4. Embryonic development protein active in cancer growth
5. Scientists win $2 million to study new pathway in development and maintenance of lymphoma
6. Stomata development in plants unraveled -- a valuable discovery for environmental research
7. Promising developments in early diagnosis and treatment of mesothelioma
8. Europe meets to discuss progress in energy research and development
9. Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
10. New genes contributing to autism and related neurodevelopmental disorders uncovered
11. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... ... 2016 , ... HOLLOWAY AMERICA, a leading custom stainless steel ... Chapter 21st Annual Vendor Exhibition on Thursday, February 18, 2016. The Rocky Mountain ... annual event, which will run from 3:00 p.m. - 8:30 p.m. at The ...
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
Breaking Biology Technology: